Background-Circulating lipid levels and myocardial lipid content (MyLC) is increased in type 2
3
The myocardium of patients with type 2 diabetes (T2D) loses its metabolic flexibility due to elevated circulating free fatty acids (FFA) levels and myocardial lipid content (MyLC) . 1 This creates a state of lipotoxicity that compromises the contractile function and promotes heart failure (HF). 1 These processes are reversible by interventions that reduce FFA fluxes. 2 MyLC, as measured by magnetic resonance proton-spectroscopy (MRS), is increased in patients with T2D and normal left ventricular ejection fraction (LVEF); 3 and a reduction in MyLC through caloric restriction improves diastolic function. 4 These observations suggest that short-term suppression of circulating lipid may have adverse cardiac effects in patients with symptomatic HF, especially in patients with elevated lipid levels such as in T2D. However, the impact of high as opposed to low circulating levels of FFA on MyLC and cardiac function in patients with T2D and HF is unknown.
We hypothesized that 1) short-term extreme changes in FFA and triglyceride levels affect MyLC in patients with T2D and HF, and that 2) suppressed as opposed to increased circulating FFA and triglyceride increase myocardial contractility and cardiopulmonary exercise capacity. The aim of the present study was hence to investigate the impact of short-term manipulation of circulating FFA and triglycerides on MyLC, cardiac systolic and diastolic function, and stress-induced contractile reserve, and the correlation between changes in MyLC and contractile function.
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Methods

Patients
We included 20 non-insulin-treated Caucasian male patients with T2D and chronic HF. The patients were stable on optimal HF medication, in New York Heart Association (NYHA) class 2-3 and had a LVEF 45% assessed by echocardiography. We excluded patients with high age (>85 years), cardiac valve disease, physical or psychological disability, creatinine >220 mM, alanine aminotransferase >3-fold the upper normal limit or myocardial infarction within the past 3 months.
MyLC was measured in the interventricular septum by MRS. Thus, we excluded patients with large septal scars visualised by echocardiography.
Design
All patients were investigated in a randomized cross-over-designed trial on two different occasions 1-6 weeks apart. They were assigned by the investigators to either high-FFA followed by low-FFA or the opposite (one to one) by drawing sealed envelopes. Patients were studied in the fasting state after 8 hours of hyperinsulinemic-euglycemic clamping at plasma glucose of 5 mM using 0. with intralipid/heparin infusion and plasma glucose was measured every second hour. On both occasions, blood samples for analysis were drawn again at t=6 hours, echocardiography was performed at t=7 hours, cardiopulmonary exercise testing at t=8 hours, and myocardial MRI followed by MRS of the heart between t=9 and t=10 hours. We were unable to repeatedly perform plasma glucose measurements in the MR scanner room. Thus, the hyperinsulinemic-euglycemic clamp was terminated before the MR investigations for safety reasons. The intralipid/heparin infusion was continued until completion of the MR investigations.
Post-processing of the data was blinded to the investigators.
Blood samples
Plasma glucose measurements were performed using HemoCue® Glucose 201 (Ängelholm, Sweden), which measures whole blood glucose and calculates plasma glucose. Additional blood samples were immediately cooled, spun, and stored at -80° Celsius until analysis. Blood samples were analyzed for levels of FFA, insulin, C-peptide, glucagon, cortisol, growth hormone (GH), insulin-like growth factor 1 (IGF-1), and adiponectin as previously described. 5 Adrenaline and noradrenaline were measured by a valid in-house time-resolved high-performance liquid chromatography method, beta-hydroxybutyrate by a commercial amperiometric method (Randoxanalysis kit RB1007, Abbott), and N-terminal pro-brain natriuretic peptide (NT-proBNP) using a commercial electrochemiluminescent assay (Roche Diagnostics, Denmark).
Echocardiography
Echocardiography was performed by a single operator using a "Vivid Seven" ultrasound scanner (GE Medical System, Horten, Norway) with a 2.5-MHz transducer. Sonovue® (Bracco, Initios Medical AB, Copenhagen, Denmark) was administered intravenously as previously described to asurements were erformed usi HemoCue® Glucose 201 (Ä g i diately cooled, spun, and stored at -80° Celsius until analysis. evels of FFA insulin C peptide glucagon cortisol growth horm asu su u u ure re re re reme me me me ment n nt nt nts w we w w w re performed using ng ng ng g H HemoCue e e e e® Gl G G G G ucose 201 (Äng a a a a asu su su su sures who o ole e b b blo ood d d gl g g g g uc c c c cose e e a an nd c c ca alcu cu cu cu cula la la la l te e es p p pl p p as s sma ma ma a a g g g g gluco co co co ose e e. . Ad Ad ddi diately cooled, spu pu u un, n n n a a a a and nd nd nd nd s s sto to to to t re re red at at at t ---80 80 80 80 80°°Ce C Ce Ce Cels ls s ls siu iu iu iu us s s s s until analysis. B e eve vels ls o of f f f f FF FF FF FF FFA A A A A i i i i ins nsul l ul l lin in i C-C-C C C pe pept ptid d id d de e g glu lu l l ca cago gon n c cor orti i ti i iso sol l l l l g gro rowt wth h ho horm rm enhance the left ventricular endocardial border delineation. 6 EchoPAC 11 software (GE-Vingmed Ultrasound, Horten, Norway) was used for analysis. LVEF was measured using the biplanemodified Simpson's method. Peak systolic longitudinal mitral plane velocities during ejection phase (S'max) were measured by tissue Doppler imaging and global strain by 2D speckle tracking as previously described. 7, 8 Measurements were performed at rest and immediately after peak exercise.
We assessed left ventricular diastolic function from mitral inflow and tissue Doppler: E/A-ratio, Edeceleration time, isovolumetric relaxation time (IVRT), and mitral plane e' (early diastolic)
velocity. Parameters were estimated as averages of either three (sinus rhythm) or five (atrial fibrillation) consecutive heart beats. All echocardiographic investigations were blinded prior to analysis.
Resting hemodynamics
Systolic and diastolic blood pressure was measured in the same arm on both visits, and mean arterial pressure (MAP) was calculated (MAP = (pulse pressure / 3) + diastolic blood pressure).
Exercise testing
A ZAN600 CPET (nSpire Health GmbH, D-97723 Oberthulba, Germany) was used. Patients performed a staged exercise bicycle test with stages lasting 1 minute and increments of 10 watts/min. Blood pressure, heart rate, and ECG were measured repeatedly every second minute.
Oxygen consumption and carbon dioxide excretion were measured continuously at rest and during the exercise test as described by the manufacturer. 
Magnetic resonance investigation
A Philips 1.5 Tesla scanner and a five-element cardiac coil were used. All MRI measurements were ECG-triggered and breath-hold was applied. MRI of the 4-chamber, the 2-chamber, and 12 slices with short-axis views was performed. Global left ventricular function was quantified using Segment v1.8 R0680 (http://segment.heiberg.se). We applied respiratory gating and ECG triggering to perform MRS and a region of interest (ROI) of 8 cm 3 (4x2x1 cm) was placed to cover the interventricular septum avoiding epicardial lipid deposits and the blood pool. A TR of 3000 ms and a TE of 26 ms were used. We performed 64 water-suppressed acquisitions followed by 16 non-
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presented as mean±standard deviation (SD out of 10%, a significance levels of 5%, and a power of 80%, we expected to be able to detect changes in left ventricular contractility (S'max, strain) of 6% (in relative percentage) and LVEF of 4% (in absolute percentage). The coefficient of variation of myocardial MRS in healthy subject is 18%. 12 Applying these parameters and complete data sets on at least ten patients, we would expect to be able to detect differences of 18% in MyLC.
Ethics
Data were collected according to the protocol at the Department of Cardiology, Department of Endocrinology and Metabolism, and the MR-center at Aarhus University Hospital, Aarhus,
Denmark. The protocol was approved by the Central Denmark Region Committee on Health
Research Ethics and informed written consent was obtained from each patient. The project is registered at http://www.clinicaltrial.gov identifier NCT01192373.
Results
Patients (Table 1, Figure 1)
Forty-three patients from our outpatient HF clinic were eligible and they were screened for inclusion between 2010 and 2011. Twenty-three were excluded either because they did not meet the inclusion criteria (N=21) or because they met the exclusion criteria according the protocol (N=2).
Twenty patients were enrolled. One suffered from cardiac arrest before the first visit (allocated to d p
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high-FFA followed by low-FFA) and another did not attend the first visit and withdrew consent (allocated to low-FFA followed by high-FFA). Eighteen patients completed echocardiography and exercise and post-exercise echocardiography on both occasions. Patients were 67±7 year of age, had an LVEF of 35±8% and were in NYHA class 2 or 3. The HF symptoms were either due to ischemic heart disease (N=15) or dilated cardiomyopathy (N=3). Two patients had atrial fibrillation as comorbidity. The mean duration of T2D was 5±4 years and HbA1c was 6.8±1.5%. All patients were on optimal medical HF treatment. Fourteen patients were on oral antidiabetic treatment and four patients on dietary treatment. Twelve patients completed the MRI and ten patients completed cardiac MRS on both occasions. Drop-outs from the MR analysis were either due to patients having a pacemaker (N=3), claustrophobia (N=2) during the scan, incomplete cardiac MR data (N=1) or technical problems during the myocardial MRS (N=2). No coronary angiography was performed before enrollment. However, all but one patient was subjected to angiography within the past three years (7 (5-13) months, median (25-75%)) which included or documented full revascularization of the arteries supplying the septum. The last patient underwent coronary angiography five years before enrollment and was diagnosed with DCM.
Substrates and hormones
FFA levels differed more than twenty-fold (0.05±0.04 (low-FFA) vs. H H H H How ow ow ow owever, , , , , al l ll bu u ut t on n ne e e e e pati ti ti ti tien en nt wa was su ubj bj bj bj bjec e e e e te te ted to o o ang n ngio o o o og g gr g g ap p p phy hy hy h h w wit th h hin nths, median (25-7 7 75% 5% 5% % 5%)) )) )) )) )) w w w w whi hi hi hi hich ch ch c c inc nc clu lu lu u ude 90.5±12.9 kg (high-FFA), p=0.09), intravenous volume infused (899±333 ml (low-FFA) vs 761±150 ml (high-FFA), p=0.06), and plasma volume calculated as previously described 13 did not differ significantly between the study arms (p=0.09) before the investigations.
MR spectroscopy (Figures 2-4)
MyLC differed by 50% between the study arms (0.78±0.59% vs 1.16±0.73%, p=0.006, Figure 2 ). 
Left ventricular function, contractility and resting hemodynamics (Table 2)
No differences between the study arms were observed in LVEF ( LVEF=1±6%, CI: -4% to 2%, p=0.60 (echocardiography); LVEF=1±4%, CI:-3% to 2%, p=0.64 (MRI)), strain or cardiac output.
S'max was higher during high-FFA than during low-FFA, and MAP was highest during high-FFA.
Diastolic parameters did not differ between high and low-FFA. a) and nd nd nd nd nd nd t t t t t t tri ri ri ri ri ri rigl gl gl gl gl gl glyc yc yc yc yc yc y er er er er er er erid id id id id id id i re 4 . However, these two correlation did not differ =0. ance. MyLC and in in n nsu su su u suli li li li lin n n n n we we we we were r re re neg eg gat at at at ativ iv iv iv ivel ely y y y y as as asso so so so soci ci ci ci ciated (r=-0.32, r (Table 2) Exercise capacity, MAP, peak O 2 consumption, LVEF, S'max and strain post exercise did not differ between study arms and neither did the diastolic parameters. The respiratory equation ratio (RER) was significantly higher during rest and peak exercise in the high-FFA arm than in the low-FFA arm. Due to the placement of the ROI during MRS, we measured regional septal strain from rest to exercise and found it to increase (p=0.02, two-way ANOVA with repeated measurements).
Discussion
In patients with T2D and HF, MyLC displayed much flexibility in response to variations in circulating lipids and correlated inversely with LVEF and positively with FFA and triglyceride levels. Short-term elevated as opposed to suppressed FFA and triglyceride levels had no detrimental effect on LVEF, strain, exercise-induced contractile reserve, or cardiopulmonary exercise capacity.
In contrast, a minor increase in S'max was observed during high lipid levels. These findings suggest circulating FFA levels on left ventricular function and cardiac efficiency. 16, 17 These discordant results may reflect differences in the pathophysiology of patients with and without diabetes and differences in the severity of the metabolic derangement such patients undergo. 18 The FFA levels differed more than 20-fold and triglyceride levels four-fold between the study arms. Even so, we detected no significant deterioration in our endpoints of LVEF, cardiac output, strain, diastolic function, contractile reserve, or cardiopulmonary exercise capacity during high-FFA as opposed to low-FFA. In contrast, we observed a minor, but significant increase in S'max in patients with high circulating levels of FFA and triglycerides. This could be due to the fact that S'max is more reproducible 19 and more sensitive to subtle contractile changes than LVEF, even by contrastenhanced echocardiography. 6 Furthermore, the present changes in S'max may have clinical relevance as it has been shown to be an independent predictor of mortality. 20 Our findings seem unlikely to be caused by changes in after-or preload. We would have expected the increase in MAP (and hence afterload) during high-FFA to decrease S'max, 21 but the opposite was observed. Even though weight and plasma volume did not differ significantly between the study arms, more fluid tended to be infused during low-FFA (approx. 140 ml, near-significant (p=0.06)) than during high-FFA. This could potentially have decreased the differences in S'max between the study arms as a volume challenge increases S'max in patients with cardiac disease. 22 However, the difference in volume was negligible. Furthermore, we would have expected these potential differences in volume load, if present, to affect preload and thus e'. 23 However, this was not observed. Our finding seems not to be explained by a confounding effect of insulin stimulation on the sympathetic nervous system 24 since insulin levels were lower during high-FFA than during low-FFA, the heart rate was unchanged, and catecholamine levels did not differ between the study arms. Furthermore, no evidence supports that GH or glucagon, 25, 26 which differed between the study arms, could have caused the observed effects in MyLC or S'max. However, differences in circulating GH concentrations could have diminished the difference in S'max as GH increases myocardial contractility. 25 C-peptide differed between the study arms, but increased C-peptide levels have no vascular effects during preserved endogenous C-peptide production. 27 Since all 
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re e e e e f f f f flu l l l l id ten e de d ded to t to be e e in i i i fu u u u use sed d d du during n ng low ow ow ow ow-F -F -FFA A A (ap a appr pr r r ro o ox o o . 14 14 14 14 40 0 0 m ml, , n n ne ng high-FFA. This s s c c c cou ou ou u ould ld ld ld ld p p p p pot ot ot ot o en e en ential al ally ly ly ly ly h h h h hav ave e e e de de e de decr cr cr cr cre e e e eased the differenc ar rms ms a as s a a vo volu lu l l me me c cha ha h h ll ll ll l en enge ge i i i i inc ncre reas ases es S S S S S'm 'max ax i i in n pa pati i ti i ien ents ts w wit i it i i h h ca card rd patients in the present study had preserved endogenous C-peptide production in both study arms, it is unlikely that different C-peptide levels biased our results. This suggests that the observed differences in S'max between the study arms may have been caused by intrinsic myocardial metabolic changes. Our findings supplement the observations by Tuunanen and coworkers, who reported that both glucose and FFA oxidation are required for optimal function of the failing heart in non-T2D HF patients. 16 Thus, this previous study and the present observations indicate that increased myocardial FFA metabolism in stable HF patients does not decrease LVEF, but on the contrary it increases stroke volume 16 and S'max. A potential explanation of this observation may be that in terms of ATP yield, thus, the decrease in cardiac fatty acid oxidation during low circulating lipid levels is not compensated for by the increase in glucose oxidation. 17, 18 Whether the discrepancies between Tuunanen et al. 16 and the present findings are rooted in differences with regard to T2D and the applied interventions are unknown. However, further studies are required to elucidate whether the failing heart responds differently to more modest reductions in circulating lipids, as previously stated. 28 Although the changes in circulating substrates were extreme in our study, the clinical significance of decreased S'max during hyperinsulinemic-euglycemic clamping and increased contractile function during hyperglycemia and elevated FFA as previously shown 29 could suggest that a major decrease in lipid load may be detrimental in patients with T2D and HF.
Short-term modulation of MyLC in patients with T2D and HF
Observational studies in patients with T2D and normal LVEF demonstrate that elevated MyLC 3 correlates inversely with diastolic function 4 and systolic strain. 30 MyLC measured in myocardial biopsies is also elevated in patients with reduced LVEF due to aortic stenosis 31 and end-stage dilated cardiomyopathy, 32 and it is even more elevated in case of coexisting T2D. 31, 32 Although we were unable to detect differences in LVEF and exercise capacity between high and low circulating tion n n n n n n. . 17 een n n n n Tu Tu Tu Tu Tuun un un un unan an an an anen en en en en et al. 16 and the prese se s s s nt finding g g ng gs ar ar ar ar are e e e e rooted in differ h h h h he e e e e ap a a plie e ed in i interv r rven n nti ti ti ti ions s s s s a are e un unkn n now ow w w wn. n. n. n n H H How we ever e er, fu fu fu fu furt r r r r he e er r r r r s s stu udie ie es he failing heart resp sp sp p pon on on n onds ds ds ds ds FFA concentrations, we demonstrated an inverse correlation between LVEF and MyLC. However, it is unknown whether this correlation reflects causality. The ability to accumulate MyLC in HF may serve as a protective buffer against detrimental lipid intermediates, 33 it may give rise to decreased energy metabolism and accumulation of toxic lipid intermediates, 34 or it may merely constitute an energy store when excess FFA is taken up by the cardiomyocyte. Thus, this finding of an inverse correlation between LVEF and MyLC needs to be addressed in future long-term studies.
However, such studies should be carefully monitored as we observed a small, but significant decrease in S'max during reduced MyLC.
In the present study, the extreme differences in circulating FFA and triglyceride levels caused a difference of 50% in MyLC between the study arms. This indicates that MyLC remains flexible to short-term extreme changes in whole-body substrate supply in patients with T2D and HF. This magnitude of change in MyLC is similar 4 or even greater 24 than that observed in previous studies of non-HF patients, and it is in accordance with findings of a high myocardial FFA uptake in case of impaired glucose tolerance. 35 FFA, triglyceride levels and MyLC correlated positively. In contrast, a previous study showed that MyLC did not increase due to elevated triglycerides 4 hours after oral lipid intake in normal test subjects. 9 However, recently it was shown that in patients with impaired glucose tolerance as compared to healthy test subjects postprandial myocardial lipid uptake is increased even though FFA levels decrease while triglyceride levels increase. 35 This suggests that results on myocardial lipid metabolism obtained in healthy subjects are not readily transferred to patients with metabolic
derangement.
The present study shows that the metabolic disturbances have not reached an "end stage" that eliminates the flexibility of lipid storage in patients with T2D and HF. Thus, the failing heart of tha a a a a a at t t t t t t My My My My My My MyLC LC LC LC LC LC LC r r r r r r rem em em em em em ema a cha es in whole-bo substrate s in atients with T2D an g e t lerance cha ha ha ha hang ng ng ng nges es es es es i i i i in w w wh w w ole-body substrate e s supply in p p p p patie ie ie ie ien nt n s with T2D an e e e e e in in in n n MyLC C i is s s sim mil l lar ar ar ar ar 4 or r r r r ev ev ven n gre e ea ater er er er er 24 
Study Limitations
Plasma glucose was increased during high-FFA. It can be argued that this might cause a minor increase in myocardial glucose uptake due to a glucose mass effect. However, this seems unlikely since FFA differed more than 20 fold between the study arms and circulating FFA levels correlate inversely with myocardial glucose uptake. 36 Similarly, ketones differed between the study arms, but to our knowledge, no human experiments support that this should affect our results.
Winhofer et al. 24 report that hyperglycemic clamp and hyperinsulinemia cause an increase in MyLC in normal subjects. We found that MyLC was lowest during hyperinsulinemic-euglycemic clamping (low-FFA). We suggest that this discrepancy is due to the large differences in triglycerides and FFA levels between our study arms.
The effect of high lipid levels on insulin sensitivity as well as hyperinsulinemia was not investigated, but could have been addressed in a 3 rd study arm by combining high FFA levels with hyperinsulinemic euglycemic clamp. Further, the applied method to lower FFA levels does not allow us to discriminate between the effects of hyperinsulinemia and suppressed circulating FFA levels. However, a previous study showed no effect on myocardial contractile function in HF patients due to short-term insulin infusion. 7 Even though no patients had T2D in this study and thus should be extrapolated with caution it suggests that the minor changes observed on S'max in the present study were unlikely caused by differences in insulin levels. Whether the applied interventions affected myocardial perfusion is unsettled and needs to be addressed in future studies.
Ideally myocardial perfusion of the septum should have been investigated at screening. However, by history, all patients completing the MRS investigations on both visits were known either to have ulin n n n n n nem em em em em em emia ia ia ia ia ia ia c c c c c c cau au au au au au ause se se se se se se a a a a a a an n b cts. We found that M C was lowest durin rinsulinemi No female participants were included in the present study and most patients were in NYHA class 2. Whether females or patients in NYHA 3 or 4 would have responded differently is unknown.
Conclusion
The failing heart of patients with T2D can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. The long-term cardiac effects of modulating myocardial lipid uptake and content await further studies.
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